Viridian Therapeutics Inc (VRDN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Viridian Therapeutics Inc (VRDN) has a cash flow conversion efficiency ratio of -0.188x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-119.65 Million) by net assets ($636.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VRDN net asset quality score to measure how much of total assets are equity-financed.
Viridian Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Viridian Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check VRDN cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Viridian Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viridian Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TX Group AG
SW:TXGN
|
0.039x |
|
Tibet Summit Resources Co Ltd
SHG:600338
|
0.052x |
|
Yusys Technologies Co Ltd Class A
SHE:300674
|
0.008x |
|
Pegasus Hava Tasimaciligi AS
IS:PGSUS
|
0.189x |
|
Huntsman Corporation
NYSE:HUN
|
-0.018x |
|
Essity AB (publ)
ST:ESSITY-A
|
0.048x |
|
Companhia Siderurgica Nacional ADR
NYSE:SID
|
0.120x |
|
IBI Inv House
TA:IBI
|
0.094x |
Annual Cash Flow Conversion Efficiency for Viridian Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Viridian Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see VRDN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $722.17 Million | $-276.39 Million | -0.383x | -10.65% |
| 2024-12-31 | $671.64 Million | $-232.32 Million | -0.346x | +16.98% |
| 2023-12-31 | $442.02 Million | $-184.17 Million | -0.417x | -75.41% |
| 2022-12-31 | $395.06 Million | $-93.84 Million | -0.238x | +18.31% |
| 2021-12-31 | $187.72 Million | $-54.58 Million | -0.291x | -17.20% |
| 2020-12-31 | $120.04 Million | $-29.78 Million | -0.248x | +89.16% |
| 2019-12-31 | $15.75 Million | $-36.06 Million | -2.289x | -337.75% |
| 2018-12-31 | $51.34 Million | $-26.84 Million | -0.523x | +28.52% |
| 2017-12-31 | $38.51 Million | $-28.17 Million | -0.731x | -103.30% |
| 2016-12-31 | $-326.00K | $-7.23 Million | 22.181x | +3447.41% |
| 2015-12-31 | $10.41 Million | $-6.90 Million | -0.663x | -79.39% |
| 2014-12-31 | $5.99 Million | $-2.21 Million | -0.369x | +35.90% |
| 2013-12-31 | $2.03 Million | $-1.17 Million | -0.576x | -298.50% |
| 2012-12-31 | $-21.44 Million | $-6.22 Million | 0.290x | -- |
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develo… Read more